Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02560948Phase 3Completed

Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Role: lead

NCT02156791Phase 2Completed

Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM

Role: lead

NCT01308021Phase 2Completed

Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis

Role: lead

NCT00813046Phase 1Completed

Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis

Role: lead

NCT01506375Phase 2Completed

Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant

Role: lead

NCT00833066Phase 1Completed

Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis

Role: lead

NCT01111279Phase 1Completed

Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis

Role: lead

All 7 trials loaded